Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 136 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin protocol Clear all
Completed Not applicable Interventional Results available

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

NCT00394524
View directory record Official record
Conditions
Diabetes or With New Hyperglycemia
Interventions
Glucommander, Standard insulin infusion algorithm
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 9, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

Oral Anti Diabetic Agents in the Hospital

NCT04416269
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM)
Drug · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 9, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Muscle Insulin Resistance in Aging (Mirage)

NCT02230839
View directory record Official record
Conditions
Insulin Resistance, Sarcopenia
Interventions
Exercise, Energy Restriction-Induced Weight Loss
Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
65 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glooko Mobile Insulin Dosing System(MIDS)
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Early Phase 1 Interventional

Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients

NCT02012465
View directory record Official record
Conditions
Lymphoma, Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Insulin protocol
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional

Physical Activity and Obesity

NCT02060240
View directory record Official record
Conditions
Obesity, Prediabetic State, Sedentary Lifestyle
Interventions
High Activity
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional

Barriers to Treatment in Obese Adolescents

NCT00167830
View directory record Official record
Conditions
Obesity
Interventions
Motivational Interviewing, Strength and Cardiovascular Conditioning, Food selection and portion control
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
11 Years to 18 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Sep 9, 2026, 5:01 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.

NCT07546942
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Autism Spectral Disorder
Interventions
Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol, Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients, FMT (Fecal Material Tranplantation), Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation
Procedure · Dietary Supplement · Behavioral + 1 more
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
10 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Hamilton, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma

NCT02507583
View directory record Official record
Conditions
Malignant Glioma, Neoplasms
Interventions
IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.
Drug
Lead sponsor
david andrews
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 9, 2026, 5:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

NCT03195140
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Predictive Low Glucose Suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
6 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Santa Barbara, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fuel Utilization, Diet Composition, and Exercise in African American Women

NCT04293367
View directory record Official record
Conditions
Obesity, Diabetes, Insulin Resistance
Interventions
High Intensity Interval Training (HIIT)
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

NCT01966978
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes
Interventions
Metformin, Detemir, Liraglutide, Insulin Aspart
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

NCT00813605
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, AMG 655, Placebo, AMG 479
Other · Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 9, 2026, 5:01 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

NCT04040894
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans

NCT01791114
View directory record Official record
Conditions
Insulin Sensitivity, Obesity
Interventions
Cold exposure, Cold exposure plus propranolol, Thermoneutral Conditions, Cold water consumption, Tepid water consumption, Exercise, Meal consumption
Other
Lead sponsor
Rutgers University
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2021 · Synced Sep 9, 2026, 5:01 AM EDT
Not listed Phase 3 Interventional

Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study

NCT01067950
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Isolated Pancreas Transplant, Intensive Insulin Therapy
Procedure · Drug
Lead sponsor
Nantes University Hospital
Other
Eligibility
25 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2010 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

NCT00125164
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 9, 2026, 5:01 AM EDT
Withdrawn No phase listed Observational

Continuous Glucose Monitoring (CGM) Substudy of the DECIDE RCT

NCT06490874
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
CGM device - Metformin group, CGM device - Insulin group
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Tuscaloosa, Alabama • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Pancreatic Clamp in NAFLD

NCT05724134
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 9, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

NCT00353834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Sep 9, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?

NCT07546409
View directory record Official record
Conditions
Prediabetes, Healthy (Controls)
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 9, 2026, 5:01 AM EDT